Reducing The Number Of Failures In Early Stage Development - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Reducing The Number Of Failures In Early Stage Development


Pharmaceutical Technology Europe
Volume 22, Issue 7

References

1. Association of Clinical Research Organizations, "Drug Development Process" (2009). http://www.acrohealth.org/

2. S. Marchetti and J.H.M. Schellens, Br. J. Cancer, 97, 577–581 (2007).

3. R.C. Garner and G. Lappin, Br. J. Clin. Pharmacol., 64(4), 367–370 (2006).

4. H. Eliopoulos et al., Clin. Cancer Res., 14(12), 3683–3688 (2008).

5. Boston Consulting Group, "Rising to the productivity challenge: a strategic framework for Biopharma" (2004). http://www.bcg.com/

6. Fund for the Replacement of Animals in Medical Experiments, FRAME UK, "Testing novel drugs in animals" (2010). http://www.frame.org.uk/

7. European Medicines Agency, "Position paper on non-clinical safety studies to support clinical trials with a single microdose" (2004). http://www.ema.europa.eu/

8. E. Abdoler et al., Clin. Cancer Res., 14(12), 3692–3697 (2008).

9. Outsourcing Pharma, "More Phase 0 studies needed to sway 'conservative pharma'" (2007). http://www.outsourcing-pharma.com/

10. FDA, "FDA's Critical Path Initiative" (2010). http://www.fda.gov/


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
24%
Attracting a skilled workforce
30%
Obtaining/maintaining adequate financing
15%
Regulatory compliance
30%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans
Source: Pharmaceutical Technology Europe,
Click here